ARCHIVES

ODAC Recommends Fludarabine Approval for Refractory CLL

This article is from The Cancer Letter archive.

Vol. 16 No. 36 | September 21, 1990

Download PDF Visit The Full Archive

Related Articles

Obituary: Lawrence Garfinkel, ACS Epidemiologist

January 22, 2010

“Landmark” Fundings Reported n Interferon Genes, Ovarian And Pancreas Markers

April 17, 1981

ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay

July 17, 2009

NCI Study Tests Method For Biomarker Validation

July 24, 2009

Studies of Oncotype DX Test Presented at ASCO Symposium

January 31, 2014

NCI Advisory Group, other Cancer Meetings

July 29, 1988